We found that different concentrations of the JMJD3 inhibitor GSK-J4 (J4) and VEGFR2 inhibitor Apatinib (Apa) combinations had a synergistic effect in suppressing osteosarcoma cells, particularly at higher concentrations (Fig. 2a). The gene discussed is KDR; the disease is osteosarcoma.